-174-
mellitus in South Asia: A consensus statement. Indian J Endocrin Metab . 
2015;19(5):577-96 
61. Aquilante CL, et al. Sulfonylurea pharmacogenomics in Type 2 diabetes: the
influence of drug target and diabetes risk polymorphisms. Expert Rev
Cardiovasc Ther. 2010;8(3):359-72
62. Ha
yward RA, et al. Follow -up of glycemic control and cardiovascular
outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 4;372(23):2197-206.
63. va
n Dalem J, et al. Risk of hypoglycaemia in users of sulphonylureas
compared with metformin in relation to renal function and sulphonylurea
metabolite group: population based cohort study. BMJ. 2016;354:i3625.
64. S
cheen AJ. Pharmacokinetic and toxicological considerations for the
treatment of diabetes in patients with liver disease. Expert Opin Drug Metab
Toxicol. 2014;10:839-5
65. Lamont, Benjamin J, Daniel J Drucker. Differential Antidiabetic Efficacy  of